ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Voyager Digital Holdings Investors With Losses to Secure Counsel Before Important January 10 Deadline in Securities Class Action – VGX
28 déc. 2022 11h19 HE
|
The Rosen Law Firm PA
NEW YORK, Dec. 28, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Voyager Earn Accounts and VGX tokens (“Voyager Investment Products”)...
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Voyager Digital Holdings Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – VGX
06 déc. 2022 18h45 HE
|
The Rosen Law Firm PA
NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Voyager Earn Accounts and VGX tokens (“Voyager Investment Products”)...
ROSEN, A LEADING LAW FIRM, Encourages Voyager Therapeutics, Inc. Investors with Large Losses to Secure Counsel Before Important Deadline – VYGR
18 févr. 2021 19h10 HE
|
The Rosen Law Firm PA
NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1,...
First Ever Star Trek™ Digital Decorations Now Available from AtmosFX®
09 avr. 2019 06h00 HE
|
AtmosFX
Seattle, WA, April 09, 2019 (GLOBE NEWSWIRE) -- AtmosFX, the Digital Decorating® company known for creating professional quality display effects for the home, announces the Star Trek: Beam Me Up...
Voyager Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Highlights
07 nov. 2018 16h10 HE
|
Voyager Therapeutics, Inc.
One-time treatment with VY-AADC demonstrates durable improvements in motor function at 18 months and beyond from ongoing Phase 1b trial Recent preclinical results for Huntington’s disease and...
Voyager Therapeutics Announces Second Quarter 2018 Financial Results and Corporate Highlights
07 août 2018 16h07 HE
|
Voyager Therapeutics, Inc.
Clinical data updates and regulatory feedback for VY-AADC during the quarter support planned pivotal program for Parkinson’s disease Pipeline programs progressing with updated preclinical data from...
Voyager Therapeutics Receives FDA Guidance on Development Path for VY-AADC for Parkinson’s Disease and Provides Clinical Update
17 juil. 2018 07h04 HE
|
Voyager Therapeutics, Inc.
Voyager continues to plan to submit a BLA for VY-AADC based on its pivotal program and Type C meeting feedback Positive interim results with VY-AADC from the Phase 1 posterior trajectory trial...
Voyager Therapeutics Appoints Andre Turenne as President and Chief Executive Officer
28 juin 2018 16h30 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., June 28, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
Voyager Therapeutics Announces First Quarter 2018 Financial Results and Corporate Highlights
10 mai 2018 07h04 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
Plantronics Unveils Voyager 104: A Headset Designed For Trucking Professionals
21 mars 2018 08h00 HE
|
Plantronics, Inc.
SANTA CRUZ, Calif., March 21, 2018 (GLOBE NEWSWIRE) -- The ability to stay connected during long hauls is a high priority for commercial truck drivers. Plantronics (NYSE:PLT), an audio pioneer and...